Literature DB >> 6359422

The limitations of conventional liver function tests.

N McIntyre.   

Abstract

Mesh:

Substances:

Year:  1983        PMID: 6359422     DOI: 10.1055/s-2008-1040779

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


× No keyword cloud information.
  7 in total

1.  Evaluation of hepatic function in liver cirrhosis: clinical utility of galactose elimination capacity, hepatic clearance of D-sorbitol, and laboratory investigations.

Authors:  E Garello; S Battista; F Bar; G A Niro; N Cappello; M Rizzetto; G Molino
Journal:  Dig Dis Sci       Date:  1999-04       Impact factor: 3.199

2.  Lidocaine and monoethylglycinexylidide serum determinations to analyze liver function of cirrhotic patients after oral administration.

Authors:  A E Muñoz; C Miguez; M Rubio; M Bartellini; D Levi; A Podestá; V Niselman; R Terg
Journal:  Dig Dis Sci       Date:  1999-04       Impact factor: 3.199

3.  [13C]Methionine breath test to assess intestinal failure-associated liver disease.

Authors:  Debora Duro; Shimae Fitzgibbons; Clarissa Valim; Chi-Fu Jeffrey Yang; David Zurakowski; Melanie Dolan; Lori Bechard; Yong Ming Yu; Christopher Duggan; Tom Jaksic
Journal:  Pediatr Res       Date:  2010-10       Impact factor: 3.756

4.  Immediate-early protooncogene expression and liver function following various extents of partial hepatectomy in the rat.

Authors:  M J Moser; Y Gong; M N Zhang; J Johnston; J Lipschitz; G Y Minuk
Journal:  Dig Dis Sci       Date:  2001-04       Impact factor: 3.199

5.  Assessment of transcutaneous bilirubinometry in hospitalized adults.

Authors:  Brian G Harbrecht; Matthew R Rosengart; Kathy Bukauskas; Mazen S Zenati; James Wallis Marsh; David A Geller
Journal:  J Am Coll Surg       Date:  2008-04-14       Impact factor: 6.113

6.  Hepatic 31P MRS in rat models of chronic liver disease: assessing the extent and progression of disease.

Authors:  I R Corbin; R Buist; J Peeling; M Zhang; J Uhanova; G Y Minuk
Journal:  Gut       Date:  2003-07       Impact factor: 23.059

7.  Silver Nanofunctionalized Stent after Radiofrequency Ablation Suppresses Tissue Hyperplasia and Bacterial Growth.

Authors:  Yubeen Park; Dong-Sung Won; Ga-Hyun Bae; Dae Sung Ryu; Jeon Min Kang; Ji Won Kim; Song Hee Kim; Chu Hui Zeng; Wooram Park; Sang Soo Lee; Jung-Hoon Park
Journal:  Pharmaceutics       Date:  2022-02-14       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.